2026 Q2 - tulosraportti
45 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sitten · MuokattuEsophagus ruptured after use of illegal slimming agent: Products labeled «retatrutid» are nevertheless sold illegally online. https://www.vg.no/nyheter/i/7paK1B/sprakk-spiseroeret-etter-bruk-av-retatrutid?utm_source=iosapp&utm_medium=share
·2 t sittenI am still buying and waiting as long as possible to sell/rebalance #fiscal year 26 An important point to note is that Novo reported free cash flow of 42.5 billion DKK for Q2# According to Novo, over 550 million people live with type 1 and type 2 diabetes. Furthermore, over 900 million people live with obesity. At the same time, there is a significant unmet need for various rare diseases, which Partly from this link: Novo is building a strong foundation to meet unmet needs in diabetes and obesity medicine
·5 t sittenis not worth the risk for me, glad that I didn't buy in.
Hi Thorstein1 Yes, I also think it's best you follow from the sidelines. I'm sure that NOVO is not for you. Especially not after a huge excessive price drop. Better to stay where you are. Then nothing has changed for you, and that's what you're most comfortable with. Thanks for sharing your point of view. The rest of us have run off with cheap Novo shares. And are patiently waiting for the next 12 months.
·6 t sittenI believe in Novo. In 2024, cagrismas was positioned as Novo's most important future product within weight loss and diabetes, but since then, the clinical results have disappointed, and sales expectations have come down significantly. The big question is whether Novo can convince investors of cagrismas's long-term potential. At the company's capital markets day in March 2024, the stock rose 8.3 percent after promising early data for the weight loss candidate zenagamtid, which was then called amykretin. It will be exciting to see what is in the pipeline. The equity fund Skagen Vækst at Skagen Fondene sold more than three quarters of its position in Novo towards the stock's peak in 2024. After the price drop, the fund has again more than doubled its position and now owns 1.8 million shares worth more than 500 million kroner. Monday's capital markets day should give investors greater certainty that Novo can actually exploit the future potential. The side effect profile for zenagamtid, and whether cagrismas differs sufficiently to become a commercial success. Right now, the market expects negative growth of. But the market is expected to grow by more than 5 percent.
·8 t sittenNovo Nordisk has entered into an agreement to acquire three obesity programs from the American biotech company Kallyope, all based on non-incretin-based mechanisms. * The most advanced program is K-554, which is described as IND-ready – i.e., ready to proceed towards clinical trials. * The two other programs include: * a potential first-in-class peptide * a small-molecule program targeting the same new target * as well as a separate small-molecule receptor agonist program, which is still in lead optimization. * The specific targets and the financial value of the agreement have not been disclosed. * The agreement was not announced via a traditional press release but was mentioned by Jacob Petersen, Novo Nordisk's Head of Global Research, and Tamara Darsow, Head of Global Business Development, on LinkedIn. Novo has subsequently confirmed to Fierce Biotech that the agreement is new. * K-554 is not a new program in itself – Kallyope has previously mentioned the candidate. What is new is that Novo is now taking over K-554 along with two additional obesity programs. Background: Kallyope is a New York-based biotech company that develops drugs based on neural signaling mechanisms, including in metabolism and migraine. The company investigates, among other things, how signals between the gut, the vagus nerve, and the brain affect appetite and food intake. In short: Novo is thus expanding its obesity pipeline with three non-incretin-based programs, with K-554 being the most advanced. This is interesting because it indicates that Novo continues to seek new mechanisms beyond GLP-1/GIP, rather than exclusively developing the next generation of incretin drugs.What can it be used for? K-554 is developed to affect the brain's/neural circuits that regulate appetite and satiety, via a mechanism not based on GLP-1 or other incretins. Kallyope describes it as a weekly injection that activates a non-incretin peptide receptor. The goal is to create satiety without necessarily eliciting the same unpleasant signals that can accompany some existing obesity treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
45 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuEsophagus ruptured after use of illegal slimming agent: Products labeled «retatrutid» are nevertheless sold illegally online. https://www.vg.no/nyheter/i/7paK1B/sprakk-spiseroeret-etter-bruk-av-retatrutid?utm_source=iosapp&utm_medium=share
- ·2 t sittenI am still buying and waiting as long as possible to sell/rebalance #fiscal year 26 An important point to note is that Novo reported free cash flow of 42.5 billion DKK for Q2# According to Novo, over 550 million people live with type 1 and type 2 diabetes. Furthermore, over 900 million people live with obesity. At the same time, there is a significant unmet need for various rare diseases, which Partly from this link: Novo is building a strong foundation to meet unmet needs in diabetes and obesity medicine
- ·5 t sittenis not worth the risk for me, glad that I didn't buy in.Hi Thorstein1 Yes, I also think it's best you follow from the sidelines. I'm sure that NOVO is not for you. Especially not after a huge excessive price drop. Better to stay where you are. Then nothing has changed for you, and that's what you're most comfortable with. Thanks for sharing your point of view. The rest of us have run off with cheap Novo shares. And are patiently waiting for the next 12 months.
- ·6 t sittenI believe in Novo. In 2024, cagrismas was positioned as Novo's most important future product within weight loss and diabetes, but since then, the clinical results have disappointed, and sales expectations have come down significantly. The big question is whether Novo can convince investors of cagrismas's long-term potential. At the company's capital markets day in March 2024, the stock rose 8.3 percent after promising early data for the weight loss candidate zenagamtid, which was then called amykretin. It will be exciting to see what is in the pipeline. The equity fund Skagen Vækst at Skagen Fondene sold more than three quarters of its position in Novo towards the stock's peak in 2024. After the price drop, the fund has again more than doubled its position and now owns 1.8 million shares worth more than 500 million kroner. Monday's capital markets day should give investors greater certainty that Novo can actually exploit the future potential. The side effect profile for zenagamtid, and whether cagrismas differs sufficiently to become a commercial success. Right now, the market expects negative growth of. But the market is expected to grow by more than 5 percent.
- ·8 t sittenNovo Nordisk has entered into an agreement to acquire three obesity programs from the American biotech company Kallyope, all based on non-incretin-based mechanisms. * The most advanced program is K-554, which is described as IND-ready – i.e., ready to proceed towards clinical trials. * The two other programs include: * a potential first-in-class peptide * a small-molecule program targeting the same new target * as well as a separate small-molecule receptor agonist program, which is still in lead optimization. * The specific targets and the financial value of the agreement have not been disclosed. * The agreement was not announced via a traditional press release but was mentioned by Jacob Petersen, Novo Nordisk's Head of Global Research, and Tamara Darsow, Head of Global Business Development, on LinkedIn. Novo has subsequently confirmed to Fierce Biotech that the agreement is new. * K-554 is not a new program in itself – Kallyope has previously mentioned the candidate. What is new is that Novo is now taking over K-554 along with two additional obesity programs. Background: Kallyope is a New York-based biotech company that develops drugs based on neural signaling mechanisms, including in metabolism and migraine. The company investigates, among other things, how signals between the gut, the vagus nerve, and the brain affect appetite and food intake. In short: Novo is thus expanding its obesity pipeline with three non-incretin-based programs, with K-554 being the most advanced. This is interesting because it indicates that Novo continues to seek new mechanisms beyond GLP-1/GIP, rather than exclusively developing the next generation of incretin drugs.What can it be used for? K-554 is developed to affect the brain's/neural circuits that regulate appetite and satiety, via a mechanism not based on GLP-1 or other incretins. Kallyope describes it as a weekly injection that activates a non-incretin peptide receptor. The goal is to create satiety without necessarily eliciting the same unpleasant signals that can accompany some existing obesity treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
45 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuEsophagus ruptured after use of illegal slimming agent: Products labeled «retatrutid» are nevertheless sold illegally online. https://www.vg.no/nyheter/i/7paK1B/sprakk-spiseroeret-etter-bruk-av-retatrutid?utm_source=iosapp&utm_medium=share
- ·2 t sittenI am still buying and waiting as long as possible to sell/rebalance #fiscal year 26 An important point to note is that Novo reported free cash flow of 42.5 billion DKK for Q2# According to Novo, over 550 million people live with type 1 and type 2 diabetes. Furthermore, over 900 million people live with obesity. At the same time, there is a significant unmet need for various rare diseases, which Partly from this link: Novo is building a strong foundation to meet unmet needs in diabetes and obesity medicine
- ·5 t sittenis not worth the risk for me, glad that I didn't buy in.Hi Thorstein1 Yes, I also think it's best you follow from the sidelines. I'm sure that NOVO is not for you. Especially not after a huge excessive price drop. Better to stay where you are. Then nothing has changed for you, and that's what you're most comfortable with. Thanks for sharing your point of view. The rest of us have run off with cheap Novo shares. And are patiently waiting for the next 12 months.
- ·6 t sittenI believe in Novo. In 2024, cagrismas was positioned as Novo's most important future product within weight loss and diabetes, but since then, the clinical results have disappointed, and sales expectations have come down significantly. The big question is whether Novo can convince investors of cagrismas's long-term potential. At the company's capital markets day in March 2024, the stock rose 8.3 percent after promising early data for the weight loss candidate zenagamtid, which was then called amykretin. It will be exciting to see what is in the pipeline. The equity fund Skagen Vækst at Skagen Fondene sold more than three quarters of its position in Novo towards the stock's peak in 2024. After the price drop, the fund has again more than doubled its position and now owns 1.8 million shares worth more than 500 million kroner. Monday's capital markets day should give investors greater certainty that Novo can actually exploit the future potential. The side effect profile for zenagamtid, and whether cagrismas differs sufficiently to become a commercial success. Right now, the market expects negative growth of. But the market is expected to grow by more than 5 percent.
- ·8 t sittenNovo Nordisk has entered into an agreement to acquire three obesity programs from the American biotech company Kallyope, all based on non-incretin-based mechanisms. * The most advanced program is K-554, which is described as IND-ready – i.e., ready to proceed towards clinical trials. * The two other programs include: * a potential first-in-class peptide * a small-molecule program targeting the same new target * as well as a separate small-molecule receptor agonist program, which is still in lead optimization. * The specific targets and the financial value of the agreement have not been disclosed. * The agreement was not announced via a traditional press release but was mentioned by Jacob Petersen, Novo Nordisk's Head of Global Research, and Tamara Darsow, Head of Global Business Development, on LinkedIn. Novo has subsequently confirmed to Fierce Biotech that the agreement is new. * K-554 is not a new program in itself – Kallyope has previously mentioned the candidate. What is new is that Novo is now taking over K-554 along with two additional obesity programs. Background: Kallyope is a New York-based biotech company that develops drugs based on neural signaling mechanisms, including in metabolism and migraine. The company investigates, among other things, how signals between the gut, the vagus nerve, and the brain affect appetite and food intake. In short: Novo is thus expanding its obesity pipeline with three non-incretin-based programs, with K-554 being the most advanced. This is interesting because it indicates that Novo continues to seek new mechanisms beyond GLP-1/GIP, rather than exclusively developing the next generation of incretin drugs.What can it be used for? K-554 is developed to affect the brain's/neural circuits that regulate appetite and satiety, via a mechanism not based on GLP-1 or other incretins. Kallyope describes it as a weekly injection that activates a non-incretin peptide receptor. The goal is to create satiety without necessarily eliciting the same unpleasant signals that can accompany some existing obesity treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt